PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28109775-0	2017	Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke"s encephalopathy.	Fedratinib	43-53	Janus kinase 2	Rattus norvegicus	27-32	
33927777-13	2021	The activated effect of cerulein on JAK2/STAT3 pathway was also reversed by JAK2 inhibitor Fedratinib or STAT3 inhibitor Stattic.	Fedratinib	91-101	Janus kinase 2	Rattus norvegicus	36-40	
34764873-8	2021	Administration of magnolol and TG-101348 or JSI-124 (both JAK2 selective inhibitors) could prevent myocardial hypertrophy and fibrosis, accompanied by the decrease in the phosphorylation level of JAK2 and STAT3.	Fedratinib	31-40	Janus kinase 2	Rattus norvegicus	58-62	
34764873-8	2021	Administration of magnolol and TG-101348 or JSI-124 (both JAK2 selective inhibitors) could prevent myocardial hypertrophy and fibrosis, accompanied by the decrease in the phosphorylation level of JAK2 and STAT3.	Fedratinib	31-40	Janus kinase 2	Rattus norvegicus	196-200	
33927777-13	2021	The activated effect of cerulein on JAK2/STAT3 pathway was also reversed by JAK2 inhibitor Fedratinib or STAT3 inhibitor Stattic.	Fedratinib	91-101	Janus kinase 2	Rattus norvegicus	76-80	
32308392-9	2020	In addition, Fedratinib not only reduced p-JAK2/JAK2 and p-STAT4/STAT4 protein expression in BMDM after treating with b-FGF and rmIL-12, but also significantly increased the tube formation of BMVES in BMVES and BMDM co-culture systems after treating with b-FGF and rmIL-12.	Fedratinib	13-23	Janus kinase 2	Rattus norvegicus	43-47	
32308392-9	2020	In addition, Fedratinib not only reduced p-JAK2/JAK2 and p-STAT4/STAT4 protein expression in BMDM after treating with b-FGF and rmIL-12, but also significantly increased the tube formation of BMVES in BMVES and BMDM co-culture systems after treating with b-FGF and rmIL-12.	Fedratinib	13-23	Janus kinase 2	Rattus norvegicus	48-52	
32947833-0	2020	Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature.	Fedratinib	74-84	Janus kinase 2	Rattus norvegicus	42-46	
32947833-0	2020	Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature.	Fedratinib	74-84	Janus kinase 2	Rattus norvegicus	48-62	
32947833-6	2020	Connectivity Map (CMap) analysis and drug sensitivity profiling predicted that a clinically approved JAK2 (Janus kinase 2)-selective inhibitor, fedratinib (also known as TG-101348), could reverse the KRAS-driven gene signature and exhibit KRAS-dependent anticancer activity in PDAC cells.	Fedratinib	144-154	Janus kinase 2	Rattus norvegicus	101-105	
32947833-6	2020	Connectivity Map (CMap) analysis and drug sensitivity profiling predicted that a clinically approved JAK2 (Janus kinase 2)-selective inhibitor, fedratinib (also known as TG-101348), could reverse the KRAS-driven gene signature and exhibit KRAS-dependent anticancer activity in PDAC cells.	Fedratinib	144-154	Janus kinase 2	Rattus norvegicus	107-121	
32947833-6	2020	Connectivity Map (CMap) analysis and drug sensitivity profiling predicted that a clinically approved JAK2 (Janus kinase 2)-selective inhibitor, fedratinib (also known as TG-101348), could reverse the KRAS-driven gene signature and exhibit KRAS-dependent anticancer activity in PDAC cells.	Fedratinib	170-179	Janus kinase 2	Rattus norvegicus	101-105	
32947833-6	2020	Connectivity Map (CMap) analysis and drug sensitivity profiling predicted that a clinically approved JAK2 (Janus kinase 2)-selective inhibitor, fedratinib (also known as TG-101348), could reverse the KRAS-driven gene signature and exhibit KRAS-dependent anticancer activity in PDAC cells.	Fedratinib	170-179	Janus kinase 2	Rattus norvegicus	107-121